Core Viewpoint - Haohai Biology is expanding its business by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membrane, despite Ruiji's ongoing financial losses and lack of performance guarantees in the transaction [1][3]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been struggling with losses of 11.77 million yuan last year and 11.29 million yuan in the first three quarters of this year [1][2]. - The transaction does not grant Haohai Biology control over Ruiji's existing team or decision-making on financial and operational matters, as the stake does not allow for consolidation in Haohai's financial reports [2]. Group 2: Financial Performance of Haohai Biology - Haohai Biology's core business has been under pressure, with a revenue decline of 7.12% and a net profit drop of 10.29% in the first half of this year compared to the previous year [1][5]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan last year, with growth rates slowing significantly [5]. - In the first three quarters of this year, Haohai's revenue was 1.899 billion yuan, down 8.47%, and net profit was 305 million yuan, down 10.63% [7]. Group 3: Market Context and Competition - The global amniotic membrane market is projected to grow from over 1.89 billion dollars last year to 3.97 billion dollars by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9]. - Analysts suggest that while the acquisition may provide strategic benefits, the ongoing losses and competitive landscape present significant challenges for Haohai Biology [9].

Investment Rating - The report indicates a weak performance in the cosmetics and medical beauty sector, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [3][4]. Core Insights - The cosmetics sector faced pressure in November, with overall GMV in the Taobao system showing weakness due to the pre-promotion of the Double 11 sales event and the rise of Douyin as a sales channel. Brands like Han Shu and Lin Qingxuan maintained stable GMV, while others like Feicui continued to grow significantly [3][9]. - The collagen medical beauty segment is expanding, with two new animal-derived collagen products approved for market entry, expected to drive growth in this area [3][9]. - The report highlights the leading market share of Minoxidil products from Mandi International in the hair loss treatment market, with a steady revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% from 2022 to 2024 [10][11]. - L'Oréal's acquisition of an additional 10% stake in Galderma, raising its total ownership to 20%, signifies a strategic shift towards the medical beauty and skin health sectors, aiming to adapt to the slowing growth in the Chinese beauty market [3][18]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index and its sub-indices for cosmetics and personal care products have shown declines of 1.2% and 1.7%, respectively, indicating underperformance compared to the Shenwan A Index [4][6]. Key Market Developments - The overall GMV for cosmetics in November was weak, influenced by earlier sales spikes in October and competition from Douyin [9]. - The approval of new collagen products is expected to enhance the supply side of the medical beauty market, with projections for continued expansion in 2026 [9][22]. Company Highlights - Mandi International has maintained a dominant position in the Minoxidil market, with its products accounting for approximately 57% and 71% of the market share in the hair loss treatment and Minoxidil categories, respectively, as of 2024 [11][13]. - The report notes that the Chinese consumer healthcare market is projected to grow from 931.3 billion yuan in 2018 to 16.42 trillion yuan by 2024, with significant growth in hair health and skin health segments [12][13].

Core Viewpoint - Haohai Biology has acquired a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membranes, despite Ruiji's ongoing financial struggles and lack of performance guarantees in the transaction [1][4]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been facing financial difficulties with losses of 11.77 million yuan in 2024 and 11.29 million yuan in the first nine months of 2025 [1][3]. - The transaction does not include any performance commitments or earn-out arrangements, posing a risk of investment loss if Ruiji's performance declines further [4]. Group 2: Haohai Biology's Business Context - Haohai Biology, the first biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, has seen a decline in its core business, with revenue and net profit dropping by 7.12% and 10.29% respectively in the first half of 2025 [1][6]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan in 2024, but growth has stagnated, with significant declines in its medical aesthetics, ophthalmology, and orthopedics segments [6][7]. Group 3: Market Potential and Competition - The global amniotic membrane market is projected to grow from 1.89 billion USD in 2024 to 3.97 billion USD by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [3][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [4][5]. - The report highlights that the November sales in the cosmetics sector were impacted by pre-Double 11 promotions and the rise of Douyin as a sales channel, leading to a weaker overall GMV [4][10]. - The collagen medical beauty segment is expanding, with two new animal-sourced collagen products approved for market, indicating growth potential in this area [4][10]. - The report emphasizes the strong market position of Mandi International in the minoxidil hair growth market, with a revenue increase from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% [4][11][12]. - L'Oréal's recent acquisition of an additional 10% stake in Galderma signifies a strategic shift towards medical aesthetics and skin health, aiming to adapt to the slowing growth in the Chinese beauty market [4][21]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 1.6%, with the Shenwan Cosmetics Index down by 1.2% and the Shenwan Personal Care Index down by 1.7% during the specified period [4][5]. - Notable stock performances included Water Sheep Co. (+5.9%) and Jinsong New Materials (+4.3%), while Hongmian Co. (-10.6%) and Juzhi Biological (-8.4%) faced significant declines [7]. Market Trends - The overall GMV for cosmetics in November was weak, influenced by the earlier sales surge in October and the emergence of Douyin as a competitive sales platform [4][10]. - The report notes that brands like Han Shu and Lin Qingxuan maintained stable GMV, while brands like Feicui continued to experience high growth [4][10]. Company Highlights - Mandi International has established a leading position in the minoxidil market, with a market share of approximately 57% in the hair loss treatment sector and 71% in the minoxidil product market as of 2024 [4][15]. - The company has shown consistent revenue growth, with a net profit increase from 2022 to the first half of 2025, indicating a robust business model [4][12][15]. Investment Recommendations - The report recommends focusing on companies with strong product lines and high profitability in the medical beauty sector, such as Ai Meike, while also suggesting attention to companies like Langzi Co. and Ru Yi Chen [4][10].

Core Viewpoint - Huaxi Biological, a leading player in the medical beauty industry, is currently facing significant challenges as the hyaluronic acid market experiences diminishing returns, leading to a decline in revenue and profit [3][5]. Group 1: Financial Performance - In the first three quarters of this year, Huaxi Biological's revenue decreased by 18.36% to 3.163 billion yuan, while net profit attributable to shareholders fell by 30.29% to 252 million yuan [5]. - As of December 5, Huaxi Biological's stock closed at 45.57 yuan, below its IPO price of 47.79 yuan, with a market capitalization of only 22 billion yuan, a drop from its peak of 140 billion yuan [5]. - By the third quarter of 2025, the company's revenue was 903 million yuan, down 15.16%, while net profit attributable to shareholders increased by 55.63% to 32 million yuan [14]. Group 2: Product and Brand Strategy - Huaxi Biological's skincare products, primarily based on hyaluronic acid, have seen a significant revenue decline, with a 33.97% drop in the first half of 2025, contributing to 40.36% of the company's main business revenue [9]. - The company has decided to eliminate several underperforming sub-brands, including Runxihe, Runxiquan, and Demarun, in an effort to focus on its core brands [9][11]. - The revenue from core brands like Kuadi and Runbaiyan has also shown signs of fatigue, with both brands expected to fall below the 1 billion yuan revenue mark by 2024 [10][17]. Group 3: Market Dynamics - The cosmetic market is experiencing intense competition, with a significant increase in the number of hyaluronic acid products, leading to market saturation and reduced consumer interest [16]. - The price war in the hyaluronic acid sector has intensified, with products like Joia's hyaluronic acid being sold at drastically reduced prices, marking the end of high-profit margins in the industry [17]. - The overall market for functional skincare products is projected to reach 211.8 billion yuan by 2025, with collagen expected to surpass hyaluronic acid as the leading ingredient [21]. Group 4: Future Outlook - Huaxi Biological is undergoing a transformation, shifting its focus from skincare to new areas such as weight loss and small nucleic acid drugs, investing 138 million yuan in a strategic partnership with Saint Pharma [24]. - The company is rebranding its skincare product line to emphasize technological innovation, indicating a shift in strategy to adapt to changing market conditions [24].

Core Viewpoint - The article emphasizes the growing importance of ESG (Environmental, Social, and Governance) practices among Chinese beauty companies, highlighting their commitment to sustainable development and social responsibility through innovative practices and reporting [2][3]. Group 1: ESG Practices and Reporting - The "Sustainable Innovation Laboratory" by Southern Metropolis Daily is collaborating with Shanghai University of Finance and Economics to evaluate and recognize outstanding ESG practices among companies, culminating in the release of the "2025 ESG Sustainable Innovation Trend Insight Report" [3]. - Major Chinese beauty companies, including Up Beauty, Proya, and Huaxi Biological, are increasingly focusing on "green packaging" as a key ESG issue, with a consensus emerging on carbon reduction and product circular consumption [3][4]. - Proya has provided detailed disclosures regarding its green packaging initiatives, including a 20% increase in sustainable materials and a 15% reduction in packaging usage intensity [4]. Group 2: Specific Initiatives by Companies - Up Beauty has implemented eight guidelines for sustainable packaging, including using FSC-certified paper and eco-friendly inks, while Huaxi Biological has improved packaging processes to minimize waste [4]. - Beitaini reported a significant increase in its bottle recycling program, achieving 2.67 million bottles recycled in 2024, which is eight times the amount from 2023 [5]. - L'Oréal has committed to ensuring that 100% of its plastic packaging is refillable, reusable, recyclable, or compostable by 2025, promoting refillable options for its products [6]. Group 3: Emerging Trends in ESG Reporting - Chinese beauty companies are beginning to incorporate "Chinese characteristics" into their ESG narratives, such as employee welfare initiatives and rural revitalization projects [7][8]. - The trend of "pure beauty" is gaining traction, with companies focusing on the safety and transparency of product ingredients, responding to consumer demand for cleaner products [14][15]. - Companies are increasingly establishing anti-corruption mechanisms, with some, like Mao Geping, including anti-corruption training in their ESG reports [10]. Group 4: Challenges and Opportunities - There is a notable lack of quantifiable targets in ESG reporting among Chinese beauty companies, particularly regarding greenhouse gas emissions and sustainable sourcing [16][19]. - The complexity of supply chains poses challenges for accurate carbon emission reporting, with many companies struggling to obtain reliable data from suppliers [19]. - The regulatory environment in China is less stringent compared to Western markets, leading to a reliance on voluntary commitments rather than mandatory compliance for ESG goals [19].

Group 1 - The medical beauty sector experienced a decline of 0.49% on December 12, with Huaxi Bio leading the drop [1] - The Shanghai Composite Index closed at 3889.35, up 0.41%, while the Shenzhen Component Index closed at 13258.33, up 0.84% [1] - A detailed table of individual stock performance in the medical beauty sector is provided [1] Group 2 - On the same day, the medical beauty sector saw a net outflow of 123 million yuan from major funds, while retail investors contributed a net inflow of 113 million yuan [2] - The net inflow from speculative funds was 9.98 million yuan [2] - A detailed table of fund flows for individual stocks in the medical beauty sector is included [2]

Core Insights - The AI+ Innovation Technology Conference held in Shanghai focused on how AI can reshape marketing growth, attracting over 200 industry experts and marketing elites, with 82.8% from brand companies and around 40% in senior management positions [1][4]. Group 1: AI in Marketing - The forum discussed various topics including AI's role in reconstructing marketing operations, practical applications in the beauty and maternal industries, and insights into consumer behavior in the AI era [1]. - Deloitte's partner highlighted the expanding breadth and depth of AI applications, emphasizing the need for companies to leverage AI for brand, talent, and data asset development [5]. - Natural brand Chando shared its AI implementation journey, focusing on transforming from traditional models to consumer-facing platforms, and the importance of data governance [6]. Group 2: Industry Challenges and Opportunities - IPG's Chief Strategy Officer discussed the rapid transformation of the marketing ecosystem due to AI, identifying challenges such as talent shortages and data security concerns [8]. - A roundtable discussion featured experts exploring whether AI serves as a cost-reduction tool or a value-creation engine in marketing [13]. - The CEO of AIGC Innovation Base presented on the practical applications of AI in retail, emphasizing the need for internal AI communities to enhance operational efficiency [14][15]. Group 3: Case Studies and Future Directions - The Chief Product Officer of Kidswant detailed the company's digital transformation journey, highlighting the launch of a large language model for the maternal and infant industry [17]. - White Elephant Food Group's design head discussed the evolution of AIGC from a productivity tool to a creative partner, showcasing successful marketing campaigns driven by AI [18]. - The CEO of SenChuang QiRui shared insights on AI's role in e-commerce, presenting solutions for cost reduction and operational efficiency, predicting a new era for AI in the industry [20]. Group 4: Awards and Recognition - The conference concluded with the iDigital Annual Digital Marketing Awards and AI Innovation Awards, recognizing contributions and innovations in the digital marketing and AI sectors over the past year [21].

Core Insights - The "2025 Skin Pharmacology and Medical Engineering Transformation Academic Conference" was co-hosted by China Pharmaceutical University and Shanghai Skin Disease Hospital, leading to the initiative for establishing the "Skin Pharmacology Professional Committee" in China [1][3] - The skin health industry in China, encompassing skin drugs, functional skincare products, and medical aesthetics, is steadily approaching a market size of one trillion yuan, but faces challenges such as a disconnect between core discipline construction and industry development needs, insufficient interdisciplinary integration, and a shortage of high-level composite talents [3][5] Group 1 - The establishment of the Skin Pharmacology Professional Committee aims to create a collaborative mechanism covering the entire chain from basic research to clinical validation, focusing on overcoming key bottlenecks in efficacy evaluation and delivery technology [3][5] - Huaxi Biological, as a core initiator, leverages its advanced positioning and core technology in aging intervention and tissue regeneration to support the committee's establishment and the development of the discipline [5][8] - The company has developed a comprehensive research and development system centered on key substances such as hyaluronic acid, proteoglycans, and collagen, forming a complete technical chain from basic research to large-scale production [5][7] Group 2 - At the conference, Huaxi Biological's director presented a report on the physiological regulation mechanisms of extracellular matrix (ECM) in skin, highlighting the synergistic effects of hyaluronic acid and sialic acid in anti-aging and repair pathways [7] - The company has made significant contributions to academic achievements and industry experience in the ECM field, advancing cutting-edge research and establishing collaborations with top international research institutions and multinational companies [7][8] - The future focus of the Skin Pharmacology Professional Committee will include innovative drug development, efficacy evaluation system construction, breakthrough skin delivery technologies, and the application of cutting-edge technologies such as skin substitute models and AI prediction models [7][8]

Group 1 - The sample adjustment for major indices such as CSI 300 and STAR 50 will be completed after the market closes on December 12, based on established criteria like market capitalization and liquidity [1][2] - The CSI 300 index will replace 11 stocks, including Shenghong Technology, Dongshan Precision, and Ruixin Microelectronics, while removing Foster, Fulete, and TCL Zhonghuan [1] - The adjustments will increase the number of samples in the information technology and communication services sectors by 4 and 2 respectively, with weightings rising by 1.46% and 0.75%, reflecting a shift towards emerging industries [1] Group 2 - The STAR 50 index will replace 2 stocks, adding Aojie Technology and Shengke Communication while removing Huaxi Biological and Hangcai Co [2] - Other indices such as CSI 500, CSI 1000, and CSI A500 will also undergo sample adjustments on the same day, changing 50, 100, and 20 stocks respectively [2] - Adjustments for indices like Shenzhen Component Index and ChiNext Index will take effect on December 15 [3] Group 3 - ETFs tracking these indices will also adjust their portfolios accordingly, with the largest total scale for CSI 300 ETFs exceeding 1.16 trillion yuan [4] - The Huaxia CSI 300 ETF (510330.SH) has a low management fee rate of 0.15% per year and has a fund size exceeding 220 billion yuan as of December 11, with an average daily trading volume of over 500 million yuan [4]